Our Ongoing Clinical Trials

Alport Study

Bardoxolone-Methyl
A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome
Click here for more information


Diabetic Kidney Disease Study

Finerenone
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Event-driven Phase 3 Study to Investigate Efficacy and Safety of Finerenone on the Reduction of Cardiovascular Morbidity and Mortality in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease in Addition to Standard of Care
Click here for more information


Resistant Hypertension Study

Spironolactone
A Randomized, Double-Blind, Placebo Controlled, Parallel Group Study of Patiromer for the Enablement of Spironolactone Use for Blood Pressure Control in Patients With Resistant Hypertension and Chronic Kidney Disease
Click here for more information


Anemia in CKD study

Daprodustat
A 52-week Open-label (Sponsor-blind), Randomized, Active-controlled, Parallel-group, Multi-center Study to Evaluate the Efficacy and Safety of Daprodustat Compared to Recombinant Human Erythropoietin in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Initiating Dialysis
Click here for more information


PKD Studies

Tesevatinib

A Double-blind Randomized Parallel Group Study of the Efficacy and Safety of Tesevatinib in Subjects with Autosomal Dominant Polycystic Kidney Disease. The primary outcome measures are to change the height adjusted total kidney volume in ADPKD patient in two year time period. 
Click here for more information about Tesevatinib in Subjects with ADPKD

A Phase 1b/2a, Safety, Pharmacokinetic and Dose-Escalation Study of KD019 in Subjects with Autosomal Dominant Polycystic Kidney Disease. The primary outcome is to analysis a two year time period of change in glomerular filtration rate (GFR) in ADPKD patients.
Click here for more information about Subjects with ADPKD

Tolvaptan
A Phase 3b, Multi-center, Open-label Trial to Evaluate the Long -Term Safety of Titrated Immediate-release Tolvaptan (OPC 41061, 30 mg to 120 mg/Day, Split Dose) in Subjects with Autosomal Dominant Polycystic Kidney Disease. The primary outcome is to determine the long-term safety of Tolvaptan in ADPKD patients. 
Click here for more information about Tolvaptan in Subjects with ADPKD